[Skip to Content]
[Skip to Content Landing]
Citations 0
July 26, 2000

β-Blockade for Patients With Heart Failure

Author Affiliations

Stephen J.LurieMD, PhD, Contributing EditorIndividualAuthor

JAMA. 2000;284(4):436-437. doi:10.1001/jama.284.4.436

To the Editor: The trial conducted by Dr Hjalmarson and colleagues1 extends current knowledge of the benefits of β-blockade in patients with CHF. The investigators were able to titrate the dosage of metoprolol CR/XL to a mean of 159 mg/d, approaching the target dosage of 200 mg/d. Eighty-nine percent of patients in the metoprolol CR/XL group and 90% of those in the placebo group were receiving angiotensin-converting enzyme (ACE) inhibitors, yet the mean dosages were only moderate; for example, 14 mg/d of enalapril in each group at baseline.